Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease

HIGHLIGHTS

• who: Takashi Maruyama and collaborators from the This prospective, open-label, single-arm, single-center study was conducted between October , and March, and eligible patients received oral canagliflozin (, mg/day) for , weeksBefore enrollment, the patients received fixed doses of conventional antidiabetic drugs (oral hypoglycemic agents and/or insulin) for , weeks, and these drugs were continued during the, week treatment period. If the investigator believed that canagliflozin presented a safety problem, its administration was discontinued. The patients continued their regular medications, such as antihypertensive drugs and lipid-lowering agents, during the study period as long as the investigators . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.